What Mixtard 30 InnoLet Treats: Main Uses and Benefits

Mixtard 30 InnoLet is applied across domains where additional symptomatic support is needed, relevant in contexts involving heightened systemic burden. It is commonly used to help with symptoms related to systemic imbalance associated with elevated blood glucose in diabetes mellitus.

Mixtard is indicated for the treatment of diabetes mellitus. This includes managing the symptomatic manifestations present in both Type 1 and Type 2 diabetes.

Symptom Management and Clinical Scenarios

This medication may assist with addressing symptom clusters that may become intense or disruptive, such as those that create noticeable interference with daily functioning. It is commonly used across conditions involving episodic or fluctuating manifestations. It is often applied during phases when symptoms become more noticeable, helping to moderate heightened physiological activity.

[Quick Fact: Symptomatic Relief for Systemic Imbalance] Mixtard 30 InnoLet contributes to easing discomfort during periods of functional strain by helping to manage symptoms related to systemic imbalance. The treatment is relevant for easing certain distressing symptoms and supports general well-being.

Regulatory References

1. European Medicines Agency therapeutic overview

Official Eligibility Rules for Mixtard 30 InnoLet

Mixtard 30 InnoLet is indicated for the treatment of diabetes mellitus in adults and in children and adolescents aged 10 years and above, according to regulatory labels. However, its use is strictly defined by conditions and population-specific restrictions.

Contraindicated Populations

The medicine is contraindicated (must not be used) in two primary circumstances:

• Patients with hypersensitivity or a confirmed allergy to human insulin or to any excipients in the formulation.
• Patients who are currently experiencing, or who are suspected of experiencing, hypoglycaemia (low blood sugar).

Mixtard 30 InnoLet must also not be administered intravenously (into a vein) and is not suitable for treating diabetic ketoacidotic coma.

Conditional Use and Special Populations

While generally allowed, special populations require close monitoring:

• Organ Function Impairment: Patients with renal (kidney) or hepatic (liver) impairment are eligible but require intensified glucose monitoring and individual dose adjustment, as organ function changes may reduce insulin requirements.
• Older Adults (ge 65 years old): Use is permitted, but the official label recommends intensified glucose monitoring.
• Pregnancy and Lactation: There are no restrictions on the use of Mixtard 30 during pregnancy, as insulin does not cross the placental barrier. Use is also considered safe during breastfeeding, posing no risk to the baby.

Interactions with other medicines and products

The official regulatory profile for Mixtard 30 InnoLet interactions is primarily classified by the pharmacodynamic effect on glucose metabolism, resulting in a documented change to the patient's insulin requirement.

Effect on Insulin Requirement	Interacting Medicinal Product Categories
Increased Hypoglycaemic Effect (Reduced Insulin Need)	Oral antidiabetic medicinal products, Monoamine oxidase inhibitors (MAOI), Beta-blockers, Angiotensin converting enzyme (ACE) inhibitors, Salicylates, Anabolic steroids, and Sulfonamides.
Decreased Hypoglycaemic Effect (Increased Insulin Need)	Oral contraceptives, Thiazides, Glucocorticoids, Thyroid hormones, Sympathomimetics, Growth hormone, and Danazol.

---

Special Interaction Cautions

Certain combinations and substances require specific constraints as defined in official product labeling:

• Beta-blockers are documented to mask the symptoms of low blood sugar (hypoglycaemia).
• Octreotide or Lanreotide may either increase or decrease the insulin requirement, leading to variable outcomes.
• Alcohol may either intensify or reduce the glucose-lowering effect of insulin, depending on the level of consumption.
• Pioglitazone in combination with insulin has been associated with reports of cardiac failure. Regulatory documentation requires monitoring for signs such as weight gain and oedema, and discontinuation of Pioglitazone is required if heart failure symptoms deteriorate.

The overall interaction structure is defined by official regulatory statements classifying the impact of co-administered agents on the human insulin response, without specifying non-pharmacodynamic mechanisms.

Mixtard 30 InnoLet delivers human insulin, a 51-amino-acid peptide hormone, in a biphasic formulation consisting of 30% soluble (rapid-acting) insulin and 70% isophane (intermediate-acting) insulin. The active molecule functions as an agonist at the insulin receptor (IR), a cell-surface transmembrane tyrosine kinase. Binding of insulin to the alpha-subunits of the IR initiates autophosphorylation of the beta-subunits.

This conformational change activates the intrinsic tyrosine kinase, triggering a cascade of intracellular phosphorylation events involving Insulin Receptor Substrate (IRS) proteins. Activation of the PI3K/Akt pathway follows, which promotes the translocation of Glucose Transporter 4 (GLUT4) vesicles to the plasma membrane of target cells, predominantly adipocytes and skeletal muscle cells.

This facilitated transport increases cellular glucose uptake. Concurrently, insulin signaling modifies hepatic processes, inhibiting gluconeogenesis and glycogenolysis while stimulating glycogen synthesis. Furthermore, the molecular activity inhibits lipolysis in adipose tissue and promotes amino acid uptake and protein synthesis, resulting in systemic modulation of energy substrate metabolism.

Using the Mixtard 30 InnoLet Device

The InnoLet is a pre-filled, disposable injection device designed for the delivery of insulin. It features a large dial and a simple dosing mechanism to assist in the administration of the suspension.

Preparing the Suspension

Before using the device, it is necessary to ensure the insulin is uniformly mixed. When the device is used for the first time, or if it has been stored, the insulin must be resuspended. This is typically achieved by rotating or tilting the device until the liquid appears uniformly white and cloudy.

General Usage Steps

• Needle Attachment: A new, sterile needle must be securely attached to the device for each injection. The device is designed to be used with specific compatible needles.
• Priming the Device: To ensure accurate dosing and to remove air bubbles, a small amount of insulin is usually expelled before the actual injection. This process confirms that the needle is not blocked and the device is functioning correctly.
• Setting the Dose: The dose is selected by turning the dial to the required number of units. The scale on the device allows for clear visibility of the selected dose.
• Injection Technique: The needle is inserted into the skin, and the push button is depressed to deliver the insulin. It is recommended to keep the needle under the skin for several seconds after the push button has been fully depressed to ensure the full dose has been delivered.

Site Selection and Rotation

Insulin is injected into the subcutaneous layer of the skin. Common injection sites include the abdomen, the thighs, the buttocks, or the upper arms. To maintain skin health and ensure consistent insulin absorption, it is important to rotate the injection site within the chosen area so that the same spot is not used repeatedly.

Post-Injection Care

After the injection is complete, the needle should be removed and disposed of safely in a puncture-resistant container. The device should be stored without the needle attached to prevent leakage and contamination.

Research Evidence / Overview of Studies for Mixtard 30 InnoLet

The Structure of Clinical Evidence for Mixtard 30

The evidence base for Mixtard 30 InnoLet (Biphasic Human Insulin 30/70) is derived from several types of studies that researched this formulation in people with diabetes. The primary evidence comes from Randomized Controlled Trials (RCTs), where patients were randomly assigned to different treatments. These studies were evaluated to explore how symptoms change over time. Other studies, known as pharmacokinetic and bioequivalence trials, were conducted to assess the pharmacokinetic profile of the formulation.

Evidence for Use in Managing Blood Glucose (Glycemic Control)

Research explored the use of Mixtard 30 in conditions characterized by fluctuating blood sugar instability. In these studies, researchers monitored several key outcomes, primarily Glycosylated Haemoglobin ( HbA1c), along with Fasting Blood Glucose and Post-Prandial Blood Glucose levels. Findings describe patterns observed in the studies related to measured blood glucose levels. Research also examined outcomes related to physical discomfort by monitoring the frequency of hypoglycemia (low blood sugar).

Comparative Studies and Measured Differences

Research explored scenarios that involved the comparison of this formulation against other insulin types. Research examined differences in blood glucose measurements and the incidence of low blood sugar events. These comparisons primarily focused on short-term changes measured during the study period.

Duration of Evidence: Follow-up and Long-Term Studies

The key clinical trials that evaluated Mixtard 30 generally involved follow-up durations that were limited, commonly lasting for 12 to 26 weeks. The limited duration of the primary controlled studies indicates that long-term outcomes are not fully established. Certainty remains low regarding the durability of these patterns over many years.

What Remains Unclear: Research Gaps and Limitations

Several limitations exist in the research base. Follow-up durations were limited in the primary controlled studies, meaning long-term effects are not fully established. Comparative evidence is lacking in some contexts, and sample sizes were modest in certain subgroup analyses. Evidence highlights what is known and what is still uncertain regarding the long-term use and research findings for Mixtard 30 InnoLet.

Common questions about Mixtard 30 InnoLet (FAQ)

---

Q: How soon after injection should I eat a meal when using Mixtard 30 InnoLet?

According to official product information, the injection must be followed by a meal or a carbohydrate-containing snack within 30 minutes of administration. This timing is recommended by official product information to help manage blood sugar levels following a meal. Taking the injection without eating is not recommended.

Q: What are the signs or symptoms of low blood sugar (hypoglycaemia)?

Hypoglycaemia, or low blood sugar, is classified as a very common side effect. Symptoms may include feeling hungry, tired, sweaty, and experiencing shaking hands or heart palpitations. Severe episodes can potentially lead to loss of consciousness or seizures. Individuals experiencing symptoms of low blood sugar are often advised to check their glucose levels.

Q: Is Mixtard 30 suitable for use in pregnant or breastfeeding women?

Official information indicates there are no restrictions on the use of this insulin during pregnancy because insulin does not cross the placental barrier. Use is also permitted during breastfeeding. However, intensified blood glucose monitoring and dosage adjustments are commonly recommended throughout pregnancy, as insulin needs typically change.

Q: How does alcohol consumption affect the blood sugar-lowering effect of Mixtard 30?

Regulatory documents state that alcohol may have variable effects. It can either intensify and prolong the glucose-lowering effect of insulin, or in some cases, it can reduce it. Due to this unpredictable impact, careful and intensified blood glucose monitoring is often recommended when alcohol is consumed.

Q: What should I do if I forget to take a dose (missed dose) of Mixtard 30?

Official guidance stresses that two doses should not be taken to compensate for a forgotten dose. Clinical practice often suggests that if the missed dose is remembered shortly after it was due, taking the usual dose may be considered. For personalized guidance on managing a missed dose, consultation with a healthcare provider is recommended.

Q: What is the active ingredient in Mixtard 30 InnoLet, and what is its purpose?

The active substance is Human Recombinant Insulin, which is structurally identical to the natural hormone. This substance is manufactured using recombinant DNA technology. Its primary purpose, as an agonist at the insulin receptor, is to help lower blood glucose levels by controlling the movement of glucose in the body and regulating the liver's glucose production.

Q: What is the typical onset, peak, and duration of action for Mixtard 30?

Mixtard 30 is a biphasic insulin, meaning it combines fast-acting and intermediate-acting components. The official product information states that the glucose-lowering effect generally begins approximately 30 minutes after injection. The action typically reaches its maximum (peak effect) between 2 and 8 hours, and the overall effect can last for up to 24 hours.

Official Storage Requirements

Storage conditions for Mixtard 30 InnoLet are determined by the pen’s status, as mandated by regulatory labeling.

Pen Status	Required Storage Condition	Prohibited Conditions
Unopened	Refrigerated (2 C to 8 C)	Do not freeze or store near the freezer.
In Use	Room Temperature (Not exceeding 30 C)	Do not refrigerate.

The in-use pen must be discarded 4 weeks (28 days) after the first use. The medicine must be kept out of the sight and reach of children and stored with the cap on to protect it from light. When storing the pen, the needle must be removed.

Official Disposal Instructions

Used needles must be disposed of in a designated sharps container. Expired or unused Mixtard 30 InnoLet must not be discarded with household waste or poured into wastewater, but should be returned to a pharmacist for proper disposal.